Single-cell transcriptomics link gene expression signatures to clinicopathological features of gonadotroph and lactotroph PitNET.

T Elise Potthoff, Carolin Walter, Daniela Jeising, Daniel Münter, Archana Verma, Eric Suero Molina, Walter Stummer, Martin Dugas, Wolfgang Hartmann, Matthias Dottermusch, Lea Altendorf, Ulrich Schüller, Sophia Scheuermann, Christian Seitz, Thomas K Albert, Kornelius Kerl
Author Information
  1. T Elise Potthoff: Department of Paediatric Haematology and Oncology, University Children's Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
  2. Carolin Walter: Institute of Medical Informatics, University of Münster, 48149, Münster, Germany.
  3. Daniela Jeising: Department of Paediatric Haematology and Oncology, University Children's Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
  4. Daniel Münter: Department of Paediatric Haematology and Oncology, University Children's Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
  5. Archana Verma: Department of Paediatric Haematology and Oncology, University Children's Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
  6. Eric Suero Molina: Department of Neurosurgery, University Hospital of Münster, 48149, Münster, Germany.
  7. Walter Stummer: Department of Neurosurgery, University Hospital of Münster, 48149, Münster, Germany.
  8. Martin Dugas: Institute of Medical Informatics, University of Münster, 48149, Münster, Germany.
  9. Wolfgang Hartmann: Division of Translational Pathology, Gerhard Domagk Institute of Pathology, University Hospital Münster, 48149, Münster, Germany.
  10. Matthias Dottermusch: Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
  11. Lea Altendorf: Department of Paediatric Haematology and Oncology, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
  12. Ulrich Schüller: Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
  13. Sophia Scheuermann: DFG Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), University of Tübingen, 72076, Tübingen, Germany.
  14. Christian Seitz: DFG Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), University of Tübingen, 72076, Tübingen, Germany.
  15. Thomas K Albert: Department of Paediatric Haematology and Oncology, University Children's Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
  16. Kornelius Kerl: Department of Paediatric Haematology and Oncology, University Children's Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. Kornelius.Kerl@ukmuenster.de. ORCID

Abstract

BACKGROUND: Pituitary neuroendocrine tumors (PitNET) are among the most common intracranial tumors. Despite a frequent benign course, aggressive behavior can occur. Tumor behavior is known to be under the influence of the tumor microenvironment (TME). However, the relationship between TME cells and aggressive tumor behavior has not been adequately explored in PitNET.
METHODS: We performed differential expression analysis as well as gene expression program identification based on single-cell RNA sequencing to comparatively characterize the transcriptome of seven gonadotroph and three lactotroph PitNET and correlate it with clinical features using bulk RNA-seq data from an independent cohort of 134 PitNET. Tumor immune infiltration was quantified via immunostaining on tissue sections of gonadotroph and lactotroph PitNET.
RESULTS: In lactotroph PitNET, we detect a highly proliferative gene profile with significantly increased expression levels in aggressively growing tumors within bulk RNA-seq data of an independent cohort of 134 PitNET samples. We also report high intratumoral heterogeneity in gonadotroph PitNET (GoPN) and lactotroph PitNET (LaPN) and identify signatures of epithelial, endocrine, and immunological gene networks in both subtypes. A comparison of their TME composition shows enrichment of SPP1 macrophages and CD4 T cells in GoPN, as well as enrichment of CD4/CD8 double-negative T cells (DN) and natural killer cells (NK) in LaPN. Also notable is the presence of proliferative lymphocytes, the occurrence of which positively correlates with more aggressive tumor behavior in the bulk RNA-seq cohort. However, increased CD8 T and NK cell abundances correlate significantly with reduced aggressiveness indicating potential anti-tumoral effects.
CONCLUSIONS: Our study expands the knowledge of the differences in cellular composition of gonadotroph and lactotroph PitNET subtypes. It lays the foundation for further studies on the influence of lymphoid cells on the variable aggressive behavior of PitNET. Regarding the treatment of drug-resistant lactotroph PitNET, proliferative lymphocytes, CD8 T, and NK cells could represent potentially valuable targets for developing new cancer immunotherapies.

Keywords

References

  1. Eur J Endocrinol. 2022 May 12;187(1):49-64 [PMID: 35521707]
  2. Front Immunol. 2021 Dec 17;12:787116 [PMID: 34975880]
  3. J Neurooncol. 2020 Sep;149(3):473-487 [PMID: 33034841]
  4. Cancers (Basel). 2022 Sep 08;14(18): [PMID: 36139536]
  5. Pituitary. 2021 Jun;24(3):359-373 [PMID: 33492612]
  6. Bioinformatics. 2018 Sep 15;34(18):3217-3219 [PMID: 29897414]
  7. Front Genet. 2021 Apr 27;12:627117 [PMID: 33986766]
  8. Front Immunol. 2021 Jul 06;12:694801 [PMID: 34295336]
  9. J Immunol. 2012 Jan 1;188(1):29-36 [PMID: 22079990]
  10. Endocr Pathol. 2015 Sep;26(3):263-72 [PMID: 26187094]
  11. Front Genet. 2022 Feb 25;13:843579 [PMID: 35281830]
  12. J Clin Endocrinol Metab. 2020 Nov 1;105(11): [PMID: 32785693]
  13. Neuroendocrinology. 2019;109(1):70-76 [PMID: 30943495]
  14. Endocrine. 2020 Mar;67(3):651-658 [PMID: 31875303]
  15. J Endocrinol Invest. 2023 Jun;46(6):1047-1063 [PMID: 37060402]
  16. Endocr Pathol. 2022 Mar;33(1):6-26 [PMID: 35291028]
  17. Nat Neurosci. 2019 Jan;22(1):78-90 [PMID: 30559476]
  18. Neuroendocrinology. 2019;109(1):20-27 [PMID: 30731464]
  19. Radiologe. 2019 Nov;59(11):982-991 [PMID: 31321467]
  20. Front Immunol. 2024 Jan 29;14:1264774 [PMID: 38347955]
  21. Front Immunol. 2020 Mar 24;11:512 [PMID: 32265939]
  22. Endocrine. 2022 Sep;77(3):500-509 [PMID: 35711030]
  23. Gastroenterology. 2021 Dec;161(6):1998-2013.e7 [PMID: 34418441]
  24. Cell Rep Med. 2023 Feb 21;4(2):100934 [PMID: 36754052]
  25. Theranostics. 2021 Feb 6;11(8):3839-3852 [PMID: 33664865]
  26. Cell. 2021 Jun 24;184(13):3573-3587.e29 [PMID: 34062119]
  27. J Immunother Cancer. 2019 Dec 5;7(1):343 [PMID: 31806053]
  28. Pathol Oncol Res. 2021 Mar 25;27:598887 [PMID: 34257554]
  29. Cancers (Basel). 2019 Oct 21;11(10): [PMID: 31640258]
  30. Endocr Rev. 2022 Nov 25;43(6):1003-1037 [PMID: 35395078]
  31. Front Cell Neurosci. 2020 Aug 06;14:198 [PMID: 32848611]
  32. Endocrine. 2021 Aug;73(2):407-415 [PMID: 33822319]
  33. Endocr Pathol. 2023 Mar;34(1):79-97 [PMID: 36797453]
  34. Front Cell Dev Biol. 2022 Mar 15;10:820562 [PMID: 35372359]
  35. Nature. 2023 Jun;618(7965):598-606 [PMID: 37258682]
  36. J Neuroendocrinol. 2023 Apr;35(4):e13263 [PMID: 37078422]
  37. Front Endocrinol (Lausanne). 2021 Dec 02;12:785050 [PMID: 34925244]
  38. Cell Commun Signal. 2020 Apr 7;18(1):59 [PMID: 32264958]
  39. Cancer Cell. 2020 Jan 13;37(1):123-134.e5 [PMID: 31883967]
  40. Biomedicines. 2021 Apr 30;9(5): [PMID: 33946142]
  41. Sci Rep. 2019 Mar 14;9(1):4487 [PMID: 30872676]
  42. Cancers (Basel). 2022 Dec 24;15(1): [PMID: 36612109]
  43. Microbiol Immunol. 2023 Feb;67(2):90-98 [PMID: 36461910]
  44. Aging (Albany NY). 2020 Nov 17;12(22):23114-23128 [PMID: 33203795]
  45. Front Immunol. 2022 Feb 10;13:816005 [PMID: 35222392]
  46. Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1738-46 [PMID: 26884166]
  47. Immunology. 2009 Apr;126(4):458-65 [PMID: 19278419]
  48. Cancer Med. 2023 May;12(10):11149-11165 [PMID: 36807772]
  49. Inflamm Regen. 2019 Jun 6;39:12 [PMID: 31182982]
  50. Genet Test Mol Biomarkers. 2014 Apr;18(4):279-85 [PMID: 24611443]
  51. Genome Med. 2024 Apr 24;16(1):60 [PMID: 38658971]
  52. Neuro Oncol. 2021 Nov 2;23(11):1859-1871 [PMID: 33908609]
  53. J Clin Endocrinol Metab. 2020 Sep 1;105(9): [PMID: 32652004]
  54. Br J Cancer. 2023 Apr;128(6):1117-1133 [PMID: 36631635]
  55. Nat Commun. 2017 Jan 16;8:14049 [PMID: 28091601]

Grants

  1. 70114624/Deutsche Krebshilfe

MeSH Term

Humans
Lactotrophs
Single-Cell Analysis
Transcriptome
Pituitary Neoplasms
Gonadotrophs
Gene Expression Regulation, Neoplastic
Female
Male
Tumor Microenvironment
Neuroendocrine Tumors
Gene Expression Profiling
Middle Aged
Adult
Cohort Studies

Word Cloud

Created with Highcharts 10.0.0PitNETlactotrophcellsbehaviorgonadotrophaggressivetumorexpressiongeneTtumorsTumorTMEbulkRNA-seqcohortproliferativeNKPituitaryneuroendocrineinfluencemicroenvironmentHoweverwellRNAsequencingcorrelatefeaturesdataindependent134significantlyincreasedheterogeneityGoPNLaPNsignaturessubtypescompositionenrichmentlymphocytesCD8Single-cellBACKGROUND:amongcommonintracranialDespitefrequentbenigncoursecanoccurknownrelationshipadequatelyexploredMETHODS:performeddifferentialanalysisprogramidentificationbasedsingle-cellcomparativelycharacterizetranscriptomeseventhreeclinicalusingimmuneinfiltrationquantifiedviaimmunostainingtissuesectionsRESULTS:detecthighlyprofilelevelsaggressivelygrowingwithinsamplesalsoreporthighintratumoralidentifyepithelialendocrineimmunologicalnetworkscomparisonshowsSPP1macrophagesCD4CD4/CD8double-negativeDNnaturalkillerAlsonotablepresenceoccurrencepositivelycorrelatescellabundancesreducedaggressivenessindicatingpotentialanti-tumoraleffectsCONCLUSIONS:studyexpandsknowledgedifferencescellularlaysfoundationstudieslymphoidvariableRegardingtreatmentdrug-resistantrepresentpotentiallyvaluabletargetsdevelopingnewcancerimmunotherapiestranscriptomicslinkclinicopathologicalGonadotrophIntratumoralLactotroph

Similar Articles

Cited By